Albert Yung-Pai Hung, Ph.D., M.D.
This page shows the publications co-authored by Albert Hung and Michael Schwarzschild.
Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned. Neurotherapeutics. 2020 10; 17(4):1393-1405.
Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics. 2014 Jan; 11(1):34-46.
Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Curr Opin Neurol. 2007 Aug; 20(4):477-83.
Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. J Parkinsons Dis. 2020; 10(2):505-510.
Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019 10 01; 93(14):e1328-e1338.
Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nat Genet. 2021 Jun; 53(6):787-793.
ß-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. Neurology. 2020 08 11; 95(6):e685-e696.
Association between a-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain. 2015 Sep; 138(Pt 9):2659-71.
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50.
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013 Oct 22; 81(17):1531-7.
Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Mov Disord. 2011 Oct; 26(12):2283-6.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.